{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["481(6)"],"submitter":["Zamo A"],"funding":["Julius-Maximilians-Universität Würzburg","NanoString Technologies"],"pubmed_abstract":["The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5<sup>th</sup> edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. This test has been previously used in clinical trials, but experience from real-world routine application is rare. We routinely applied the Lymph2Cx assay to day-to-day diagnostics on a series of 147 aggressive B-cell lymphoma cases and correlated ou"],"journal":["Virchows Archiv : an international journal of pathology"],"pagination":["935-943"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9734243"],"repository":["biostudies-literature"],"pubmed_title":["Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series."],"pmcid":["PMC9734243"],"pubmed_authors":["Zamo A","Gerhard-Hartmann E","Rauert-Wunderlich H","Rosenwald A","Anagnostopoulos I","Scott DW","Ott G"],"additional_accession":[]},"is_claimable":false,"name":"Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series.","description":"The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5<sup>th</sup> edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. This test has been previously used in clinical trials, but experience from real-world routine application is rare. We routinely applied the Lymph2Cx assay to day-to-day diagnostics on a series of 147 aggressive B-cell lymphoma cases and correlated ou","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-22T05:38:32.501Z","creation":"2024-11-14T06:59:03.85Z"},"accession":"S-EPMC9734243","cross_references":{"pubmed":["36219238"],"doi":["10.1007/s00428-022-03420-6"]}}